Konstantin Doberer

List of Publications by Year
in descending order

27	744	840776 11	752698 20
papers	citations	h-index	g-index

27	27	27	929
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized Clinical Trial of Antiâ€“IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 708-722.	6.1	101
2	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients. JAMA Internal Medicine, 2022, 182, 165.	5.1	100
3	Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients. Journal of Infectious Diseases, 2018, 218, 1191-1199.	4.0	93
4	The therapeutic challenge of late antibodyâ€mediated kidney allograft rejection. Transplant International, 2019, 32, 775-788.	1.6	89
5	Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipientsâ€”A prospective observational trial. American Journal of Transplantation, 2020, 20, 2081-2090.	4.7	64
6	CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation, 2021, 105, 451-457.	1.0	57
7	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials, 2019, 20, 37.	1.6	48
8	Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 1934-1939.	4.0	46
9	Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial. Transplantation, 2021, 105, 2112-2118.	1.0	29
10	PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1913-1922.	2.4	22
11	Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Frontiers in Medicine, 2020, 7, 114.	2.6	20
12	Diagnostic value of donorâ€derived cellâ€free DNA to predict antibodyâ€mediated rejection in donorâ€specific antibodyâ€positive renal allograft recipients. Transplant International, 2021, 34, 1689-1702.	1.6	16
13	Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opinion on Emerging Drugs, 2022, 27, 151-167.	2.4	13
14	New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment. Current Opinion in Organ Transplantation, 2021, 26, 97-105.	1.6	11
15	Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes. Scientific Reports, 2017, 7, 13524.	3.3	8
16	Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials, 2022, 23, 270.	1.6	8
17	Antiâ€interleukinâ€6 antibody clazakizumab in late antibodyâ€mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transplant International, 2021, 34, 1542-1552.	1.6	7
18	Immunoadsorption Combined with Membrane Filtration to Counteract Early Treatment-Refractory Antibody-Mediated Rejection. Blood Purification, 2020, 49, 576-585.	1.8	5

#	Article	IF	Citations
19	Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection. Frontiers in Medicine, 2022, 9, 817127.	2.6	2
20	Proteinuria in Deceased Kidney Transplant Donors for Prediction of Chronic Lesions in Pretransplant Biopsies: A Prospective Observational Study. Transplantation, 2022, Publish Ahead of Print, .	1.0	2
21	P1624TORQUE TENO VIRUS FOR RISK STRATIFICATION OF GRAFT REJECTION AND INFECTION IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE OBSERVATIONAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
22	High-activity Classical and Alternative Complement Pathway Genotypesâ€"Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival. Transplantation Direct, 2020, 6, e534.	1.6	1
23	Determinants of the intercept and slope of glomerular filtration rate in recipients of aÂlive donor kidney transplant. Wiener Klinische Wochenschrift, 2021, 133, 107-117.	1.9	1
24	P1643TORQUE TENO VIRUS FOR RISK STRATIFICATION OF SUBCLINICAL GRAFT REJECTION AFTER KIDNEY TRANSPLANTATION- A PROSPECTIVE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
25	An authorâ€™s reply to the editorial â€œTorque Teno virus load as a surrogate marker for the net state of immunosuppression: The beneficial side of the viromeâ€• American Journal of Transplantation, 2020, 20, 2280-2281.	4.7	0
26	MO1022: Torque Teno Virus Load in Kidney Transplantation: Association with Donor and Recipient Characteristics and Clinical Follow-Up Data. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
27	MO1023: Effects of Bortezomib on Complement Fixation and IGM Reactivity in Late Abmr â€" Results of A Randomized Controlled Trial (The Borteject Trial). Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0